Massachusetts House Bill H1581

Massachusetts 2025-2026 Regular Session

• Introduced: 2/27/25
• Refer: 2/27/25

Caption

Specifying an electronic system to ensure that sales of certain products containing pseudoephedrine (PSE) do not exceed limits established under federal law

Impact

If enacted, HB 1581 will amend Chapter 94C of the General Laws, establishing stringent tracking and verification measures in the sale of pseudoephedrine-containing products. Retailers will be required to maintain detailed transaction logs, which include personal identification of the purchasers, quantities sold, and timestamps. Furthermore, the bill mandates that retailers not only implement the electronic stop-sale system but also provides an immunity clause to protect them from civil liabilities when they act in compliance with the system, thus incentivizing adherence without the fear of potential legal repercussions.

Summary

House Bill 1581 aims to establish a regulated electronic system for the sale of products containing pseudoephedrine (PSE), particularly those commonly used in cold and allergy medications. This legislation seeks to create a 'real-time stop sale system' that allows pharmacies and other retailers to verify the quantity of pseudoephedrine being sold to individual customers, thus ensuring compliance with federal and state limits. The bill stipulates that no person may purchase more than 3.6 grams of pseudoephedrine per day or 9 grams in a 30-day period, reflecting existing federal law guidelines aimed at curbing the illegal production of methamphetamine.

Contention

The introduction of HB 1581 has prompted discussions about its implications for local regulations. The bill preempts any local laws governing the sale of products containing pseudoephedrine, meaning state law would take precedence over local statutes. This aspect has raised concerns among some local jurisdictions that believe it could limit their ability to manage specific community needs effectively. Additionally, the requirement for retailers to implement an electronic system raises questions regarding costs and operational burdens, particularly for smaller pharmacies. The balance between preventing misuse of pseudoephedrine and ensuring accessible and efficient retail practices remains a focal point of discussion among legislators and constituents alike.